Please login to the form below

Not currently logged in
Email:
Password:

Abbott to acquire Facet Biotech

Abbott is to acquire Facet Biotech in a deal valued at approximately $722m, strengthening Abbott's capabilities in biologics in immunology and oncology

Abbott is to acquire Californian-based Facet Biotech in a deal valued at approximately $722m. The move will strengthen Abbott's capabilities in biologics in immunology and oncology.

The acquisition gives Abbott access to daclizumab, a mid-stage biologic being developed in collaboration with Biogen Idec for the treatment of patients with multiple sclerosis. The drug is expected to move into phase III testing in the second quarter of 2010.

Facet's oncology portfolio includes several compounds being developed in collaboration with other partners, and will complement Abbott's own compounds in mid- to late-stage trials, including ABT-263, ABT-888, and ABT-869.

Under the terms of the agreement, Abbott will begin a tender offer to purchase all outstanding shares in Facet Biotech at $27 per share in cash, resulting in a net cost of about $450m. The stock offer represents a 67 per cent premium to Facet's closing share value on Tuesday. In addition, the purchase price includes $272m, representing Facet Biotech's projected cash and securities.

The deal is expected to close in the second quarter of 2010.

10th March 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

Products come and go, but a pharma company’s most valuable, durable asset is its reputation, writes Duncan Mackenzie-Reid and Simon Grist
...
Erik
A quest for innovative solutions
UCB looks to the future through a PRISM...
Big data, privacy and the rise of genomic testing
Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big...

Infographics